BRAIN and NERVE Shinkei Kenkyu no Shinpo Volume 71, Issue 9 (September 2019)

Development of Novel Therapeutics for Core Symptoms of Autism Spectrum Disorder: An Integrative Approach of Clinical Trials, Neuroimaging, and Genomics Hidenori Yamasue 1 1Department of Psychiatry, Hamamatsu University School of Medicine Keyword: 自閉スペクトラム症 , アスペルガー症候群 , 発達障害 , 神経画像 , 神経ペプチド , autism , Asperger , developmental disorders , neuroimaging , neuropeptide pp.971-980
Published Date 2019/9/1
  • Abstract
  • Look Inside
  • Reference


Discrepancies in the efficacy between single-dose and repeated administrations of oxytocin on autism spectrum disorder (ASD) indicate a time-course change in efficacy. However, the hypothesis cannot be tested without a repeatable, objective, and quantitative measurement of the core symptoms of ASD. The author's research group comprehensively examined recently examined reported single-site exploratory (n=18, crossover) and multi-site confirmatory (n=106, parallel-group), double-blind, placebo-controlled trials of six-week intranasal oxytocin (48 IU/day) in adult males with ASD. The outcomes were statistically representative values of the objectively quantified facial expression intensity during a semi-structured social interaction in the Autism Diagnostic Observation Schedule. The quantitative facial expression analyses on data from these two independent clinical trials successfully detected and verified the therapeutic effect of repeated administrations of intranasal oxytocin on autistic features in facial expressions during social interaction. Furthermore, for the first time, the recent study demonstrated a time-course change in the efficacy: deterioration during the repetitive administration phase and preservation during the post-treatment phase. Together with our recent study regarding neurochemical mechanisms of deteriorating efficacy of oxytocin, the findings are expected to promote further development of optimized objective, quantitative, and repeatable outcome measures for autistic social deficits and to establish an optimized regimen of oxytocin treatment in ASD.

Copyright © 2019, Igaku-Shoin Ltd. All rights reserved.


BRAIN and NERVE-神経研究の進歩
71巻9号 (2019年9月)
電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院